Founded in 1991, Beijing Wantai has grown from a small laboratory to one of the biggest and most influential Chinese manufacturers of in vitro diagnostic tests and is leading the way in blood transfusion and infectious immunology.
As Asia-Pacific’s largest HIV diagnostic reagent production base we have dominated the reagent market for the past 15 years; our Hepatitis C and Syphilis detection reagents have been top products in the market for several years.
At Beijing Wantai we are specialized in manufacturing ELISA kits and rapid tests for infectious disease diagnostics, producing and distributing chemiluminescence and clinical chemistry reagents, and researching – as well as manufacturing – quality control materials.
We service both international and domestic customers including blood banks, hospitals and clinics, reference laboratories, border inspection centres, blood-processing companies, and research institutes.
Our headquarters are located in the biotechnology heart of Beijing at Zhongguancun Life Science Park Beijing.
Our Beijing plant is the largest manufacturing base for the production of immunodiagnostic reagents in China. Our state-of-the-art production facilities are GMP, ISO9001 and ISO13485 certified and our products undergo strict quality and cost controls. Most of our products bear the CE marking including our HCV, HBsAg and HIV ELISA kits. Our HIV Rapid test and HIV ELISA kit are WHO pre-qualified ensuring that that test kits can be used globally where they are needed.
Beijing Wantai is the biopharma arm of Yangshengtang Group and employs more than 1500 people.
Statement against modern slavery and child labor: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. strongly condemns and resists modern slavery and child labor. Wantai abides by the laws and regulations related to modern slavery and child labor and strictly performs its duties that include providing humanized working conditions, not forcing employees to work longer than the maximum working hours stipulated by national laws and regulations, paying employees in time and ensuring that modern slavery and child labour do not occur in any part of its business. Any employee or supplier of Wantai who violates this provision will have its labor or cooperative relationship terminated. This statement applies to Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. and its directly or indirectly controlled subsidiaries.
Statement on Anti-corruption: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has always taken "Making contributions to human health" as its mission and "Quality for survival and scientific and technological innovation for development" as its purpose. Wantai believes that commercial bribery violates the basic principles of market economy, destroys market order and hinders fair competition. In order to prevent corruption, Wantai requires all its employees not to offer bribes directly or indirectly to any entity or individual in order to obtain business opportunities. Likewise, if any partner performs the above mentioned actions on Wantai’s staff in order to obtain business opportunities, the staff must refuse and report to the company. In the future, Wantai will take other positive and effective measures such as signing agreements and formulating management systems to continuously crack down on commercial bribery to promote an open, transparent and fair business environment. This statement applies to Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. and its directly or indirectly controlled subsidiaries.
Founded in 2005, Xiamen Innovax Biotech CO., LTD. (INNOVAX) is dedicated to developing innovative vaccines.
Xiamen Innovax Biotech Co., Ltd. (INNOVAX) is a subsidiary of Wantai and is a leading company in the field of developing, manufacturing and marketing innovative vaccines with its headquarter and manufacture facilities based in Xiamen, China. In collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) of Xiamen University, Innovax has established a core-platform using DNA recombinant technology to express protein in E. coli for vaccine production. Based on this platform, the world’s first hepatitis E vaccine, Hecolin® was launched in China in October 2012.
We have also developed two vaccines against HPV: Cecolin® (approved in China in December 2019) and Cecolin 9™ (clinical trial approved). Furthermore, preclinical studies are in progress for a vaccine against Rotavirus as well as a Recombinant Hepatitis B Protein Injection.
